We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
+20.43%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$869M
AUM Growth
-$37.3M
Cap. Flow
-$52.6M
Cap. Flow %
-6.05%
Top 10 Hldgs %
62.94%
Holding
54
New
3
Increased
9
Reduced
7
Closed
6

Top Buys

Rank Stock Value
1
VECT
VectivBio Holding AG Ordinary Shares
VECT
+$18.8M
2
GERN icon
Geron
GERN
+$9.06M
3
ATXS
Astria Therapeutics
ATXS
+$7.02M
4
PCVX icon
Vaxcyte
PCVX
+$6.87M
5
CMPX icon
Compass Therapeutics
CMPX
+$6.21M

Top Sells

Rank Stock Value
1
HRMY icon
Harmony Biosciences
HRMY
+$43.7M
2
RLMD icon
Relmada Therapeutics
RLMD
+$26.4M
3
ASND icon
Ascendis Pharma A/S
ASND
+$15.1M
4
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$8.67M
5
STSA
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
+$7.39M

Sector Composition

Rank Sector Weight
1 Healthcare 98.63%
2 Materials 1.37%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RLMD icon
51
Relmada Therapeutics
RLMD
$563M
– –
-713,238
Closed -$26.4M
ISEE
52
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-483,413
Closed -$8.67M
STSA
53
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
– –
-1,232,394
Closed -$7.39M
MTCR
54
DELISTED
Metacrine, Inc. Common Stock
MTCR
– –
-146,426
Closed -$71K
1 2
3

Similar funds

FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.4% 1-Year Est. Return
MB
MidFirst Bank Oklahoma City, Oklahoma $1.21B AUM
CCM
Condor Capital Management Martinsville, New Jersey $1.2B AUM 13.18% 1-Year Est. Return
TIM
Tortoise Investment Management White Plains, New York $1.21B AUM 13.04% 1-Year Est. Return
CS
Central Securities New York $1.21B AUM 19.91% 1-Year Est. Return
KOC
Koss-Olinger Consulting Gainesville, Florida $1.19B AUM 15.91% 1-Year Est. Return

Vivo Capital's Q4 2022 Portfolio in Review

As of Q4 2022, Vivo Capital held 54 positions worth $869M, down 4.1% from $906M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Vivo Capital withdrew a net $52.6M in Q4 2022, closing 6 positions and reducing 7 holdings. Its most notable exit was Relmada Therapeutics, an estimated $26.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Materials.

Against the trend, Vivo Capital opened a new position in VectivBio Holding AG Ordinary Shares worth $20.2M.

  • Vivo Capital's largest Q4 2022 buy was VectivBio Holding AG Ordinary Shares: 2,333,300 shares worth $20.2M.
  • Vivo Capital added most to Geron in Q4 2022, an estimated $9.06M increase.
  • Vivo Capital's biggest Q4 2022 reduction was Harmony Biosciences, cutting an estimated $43.7M.
  • Vivo Capital fully exited Relmada Therapeutics in Q4 2022, selling an estimated $26.4M.
  • Vivo Capital's ten largest holdings make up 63% of its $869M portfolio in Q4 2022.
  • Vivo Capital opened 3 new positions and closed 6 in Q4 2022.
  • Vivo Capital's portfolio value fell 4.1% quarter-over-quarter to $869M.

Based on Vivo Capital's 13F filing for Q4 2022, filed 13 Feb 2023.